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ABSTRACT 
Objective: The electrochemical behaviour of Desloratadine (DLTD) in pharmaceutical and human urine samples at glassy carbon electrode was 
investigated by cyclic voltammetry (CV) and square wave voltammetry (SWV).  
Methods: A well defined reduction peak was observed at potential -1.55V in phosphate buffer solution (PBS) in basic medium. The reduction 
process was observed to be irreversible over the pH range from pH 2.0 to pH 10.0. The influence of different parameters such as the effect of pH, 
scan rate and concentration of the drug was studied. The probable reaction mechanism involved in the reduction of DLTD was also proposed. A 
SWV method with good recovery and accuracy was obtained for the determination of DLTD in pharmaceutical formulations and urine samples.  
Results: The peak currents were found to be linearly dependent on the concentration range of 2.55x10-5to 1.5x10-3M of DLTD. The limit of detection 
(LOD) and limit of quantification (LOQ) were found to be 2.75x 10-9M, 3.20x 10-7
Conclusion: The proposed method was successfully applied for determination of DLTD in pharmaceutical and human urine samples. 
 M respectively.  
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INTRODUCTION 
Desloratadine (DLTD) is a tricyclic antihistamine, which has a 
selective and peripheral H1-antagonist action. It is an antagonist at 
histamine H1 receptors and an antagonist at all subtypes of the 
muscarinic acetylcholine receptor. Its chemical name is 8-chloro-6, 
11-dihydro-11-(4-piperidinyidene)-5H benzo [5,6] cyclohepta 
[1,2,b] pyridine and has a structure as below (Fig.1). It has a long-
lasting effect and in moderate and low doses, does not 
cause drowsiness, because it does not readily enter in to the central 
nervous system [1]. Unlike other antihistamines, DLTD is also 
effective in relieving nasal congestion, particularly in patients 
with allergic rhinitis [2]. A number of papers regarding the analytical 
approach for DLTD determination in plasma and pharmaceutical 
formulations are mentioned in literature [3-8].  
n recent times a bio analytical method for determination DLTD and 
its metabolite 3-OH-DLTD using ultra high pressure liquid 
chromatography in conjunction with mix mode solid phase 
extraction is published which involved gas chromatography with 
nitrogen– detectionphosphorus  withchromatographyliquid
anddetectionfluorescence  ultraviolet detection or mass 
spectrometric detection 
MATERIALS AND METHODS 
[9-15]. Mara et al. Reported electrochemical 
behaviour or voltammetric methods for determination of DLTD and 
its metabolite [16].  In the present work focused on an 
electrochemical determination of DLTD in pharmaceutical and 
human urine samples using glassy carbon electrode. It was chosen to 
get the reduction mechanism of >C=N< group by employing 
advanced electrochemical techniques such as cyclic voltammetry, 
square wave voltammetry. Therefore, a rapid and sensitive 
voltammetric method has been applied to determination of DLTD in 
pharmaceutical and spiked urine samples. 
Apparatus  
Electrochemical studies were carried out by Autolab PG STAT101 
supplied by Metrohm Autolab B. V., The Netherlands. A three 
electrode systems comprising of a glassy carbon electrode as a 
working electrode. Glassy carbon electrode (GCE-3 mm) obtained 
from Metrohm India Ltd Chennai. Saturated Ag/AgCl/KCl as a 
reference electrode and Pt wire as a counter electrode. An Elico LI-
120 pH meter supplied by Elico Ltd, Hyderabad, India was used to 
determine the pH of the buffer solution. 
 
Fig. 1: Structure of desloratadine (DLTD) 
 
Chemical and reagents 
A stock solution of DLTD (1.0×10-3 M) was prepared by dissolving of 
DLTD in methanol and it was further with same solvent diluted up to 
100 ml to give appropriate concentrations. The solution was stable 
for 2 weeks in a refrigerator at about 4°C. The working solutions of 
the drug were prepared daily by diluting the stock solution with a 
selected supporting electrolyte. The supporting electrolyte was 
usually phosphate buffer containing Na2HPO4 and NaH2PO4
Analytical procedure 
. Double 
distilled water was used throughout the work. All other solvents and 
reagents used throughout this study were of analytical grade. 
After 10 ml of phosphate buffer (PBS) of pH 9.0 was placed in the 
electrochemical cell, to this certain volume of standard solution 
(2.55x10-5
Assay of tablets 
M) of DLTD was added and de-aerated with pure nitrogen 
for 10 min. Then the voltammograms were recorded using cyclic 
voltammetry and square wave voltammetry over the potential range 
-0.90V to -1.75V vs Ag/AgCl/KCl. All measurements were carried out 
at room temperature.  
The tablets of DLTD were obtained from local commercial sources. 
Ten tablets were weighed accurately and ground to a fine powder.  
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A portion of the powder equivalent to 1 mM DLTD was transferred 
to a 100 ml volumetric flask and completed to volume with distilled 
water and sonicated for 15 min to affect complete dissolution. The 
sample from the clear supernatant liquor was withdrawn and 
quantitatively diluted with the selected supporting electrolyte. The 
content of the drug in tablet was determined referring to the 
calibration graph using square wave voltammetry. 
RESULTS AND DISCUSSIONS  
Cyclic voltammetric study 
The electrochemical behaviour of DLTD in pharmaceutical and 
human urine samples at glassy carbon electrode was investigated 
using cyclic voltammetry (CV) at various pH values. The cyclic 
voltammograms are obtained for 2.55x10-5
 
M DLTD solution at a 
scan rate of 50 mV/s and exhibits a well-defined irreversible 
cathodic peak at about -1.55V at glassy carbon electrode in 
phosphate buffer solution of pH 9.0. The results are shown in Fig. 2. 
The drug DLTD exhibits reduction peak with lowest current and 
negative potentials. However, no peak was observed in the reverse 
scan, suggesting that the reduction process is an irreversible one. 
The reduction product in turn did not show any oxidized peak at the 
extended ranges of potential. According to the previous results 
presented, it is supposed that the pathway of DLTD reduction at the 
unsaturated C=N bond of pyridine ring is reduced on the glassy 
carbon electrodes preferably of the protonated form, and involves 
transfer of two electrons, yielding saturated bond. The proposed 
reduction mechanism is shown in scheme 1. 
 
Fig. 2: Typical cyclic voltammograms of DLTD in PB solution, 
concentration: 2.55x10-5
 
M at glassy carbon electrode in 
different pH values from pH 4.0-10.0 (a to d) 
 
Scheme 1: Reduction mechanism of DLTD 
 
Effect of pH 
The pH of the solution is a significant aspect affecting the rate of 
accumulation process and the rate of electrode reaction. The 
influence of pH on the peak current was studied at glassy carbon 
electrode for DLTD of concentration 2.55x10-5
 
M between pH 2.0 to 
pH 12.0. It was evident from that the maximum peak current was 
obtained at pH 9.0. When the pH was increased, the peak potential 
shifted towards more negative values indicating proton 
participation in the reduction process. The well defined 
voltammograms were obtained, which are strongly dependent on 
buffers and pH of the medium. Phosphate buffer was used in the 
study and the best results in terms of peak shape were obtained at 
pH 8.0 to pH 12.0, but most intense peak was observed at pH 9.0. 
From the plot of current vs pH (Fig. 3) and potential vs pH (Fig.4), it 
is clearly shows that with increase from pH 4.0 to pH 8.0 It may be 
due to less availability of protons at lower pH. Therefore, pH 9.0 was 
chosen as optimum one for the study of DLTD reduction. 
 
Fig. 3: The plot the of current vs pH of DLTD in PB solution, 
concentration: 2.55x10-5
 
M at glassy carbon electrode in 
different pH values 
 
Fig. 4: The plot of the potential vs pH of DLTD in PB solution, 
concentration: 2.55x10-5
 
M at glassy carbon electrode in 
different pH values. 
Effect of scan rate  
The influence of the scan rate was investigated. The results 
suggested that square wave voltammetric peak current reached 
maximum value when the scan rate was 50 mV. As for the scan rate; 
the current response with increasing the scan rate of 50mVs-1 to 100 
mVs-1gave the maximum response (Fig 5). Accordingly, the optimum 
conditions for recording a maximum developed and sharper peak for 
DLTD are tacc:  60 sec., Eacc:  -1.55V, scan rate: 50 mVs-1 and pulse 
amplitude: 50 mV, optimum temperature: 25o
Square wave voltammetric study 
C. 
In order to develop a voltammetry method for determining the 
DLTD drug in pharmaceutical and human urine samples, we selected 
the square wave voltammetric mode, because the peaks are sharper 
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and enhanced defined at the lower concentration of DLTD than those 
obtained by cyclic voltammetry. According to the obtained results, it 
was possible to apply this technique to the quantitative analysis of 
DLTD. The phosphate buffer solution of pH 9.0 was selected as the 
supporting electrolyte for the quantification of DLTD as it gave 
maximum peak current at pH 9.0. Square wave voltammograms 
obtained with increasing amounts of DLTD showed that the peak 
current increased linearly with increasing concentration shown 
in Fig. 6. 
 
Fig. 5: Effect of scan rate on DLTD at pH 10.0 in PB solution at 
concentration 2.55×10-5
 
M at different scan rates: (a) 50 mV/s 
(b)100 mV/s (c)150 mV/s (d) 200mV/s (e) 250mV/s 
 
Fig. 6: Typical square wave voltammograms of DLTD in PB 
solution pH 9.0, concentration: 1.0x10-3M to 2.55x10-5
 
M (a to e) 
at glassy carbon electrode 
 
Fig. 7: Calibration plot of the DLTD in PB solution pH, at 
different concentrations at glassy carbon electrode 
Calibration curve 
In the square wave voltammetric mode a well-defined wave/peak 
obtained at pH 9.0 is used in the analytical estimation of DLTD in 
pharmaceutical and human urine samples. Both standard addition 
and calibration methods are used for the analysis of DLTD in 
pharmaceutical formulations and urine samples. The peak current is 
found to vary linearly with the concentration of DLTD over the range 
from 10μM to 70μM with the lower detection limit of 2.75x 10-9
 
M 
(Fig.7). The calibration curve has been found to be linear with the 
equation 5  = 0.6285+0.018 with a correlation coefficient of 0.9862 
and relative standard deviation values are found to be 1.55%, 
respectively for five replicates (Table 1). 







1 5 4.98  99.60 1.55 
2 10 9.90 99.00 1.70 
3 15 14.80 98.66 2.45 
Urine samples 
1 5 4.86 97.20 1.85 
2 10 9.68 96.80 2.35 
3 15 14.47 96.46 2.75 
*Average five determinations 
 
CONCLUSION 
The electrochemical behaviour of DLTD in pharmaceutical and 
human urine samples at glass carbon electrode was examined in 
phosphate buffer over the pH range from 2.0 to 12.0 by square wave 
voltammetry and cyclic voltammetric methods. The drug exhibits 
lower current and negative potentials with lower detection limit of 
2.75x 10-9
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